Anti-Mouse Vγ2 TCR – Purified in vivo GOLD™ Functional Grade

The UC3-10A6 clone is used in in vivo mouse studies to specifically deplete ?? T cells that express the V?2 T cell receptor (TCR). When administered to mice, this monoclonal antibody binds an epitope on the delta chain of the mouse V?2 TCR and eliminates V?2+ ?? T cells through immune mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).

Key details:

• Target specificity: Binds the V?2 TCR (also known as V?4 in alternate nomenclature), found on a substantial subset of ?? T cells in mouse thymus, lymphoid organs, skin, lungs, and gut.
• Functional use in studies: The main experimental application is the selective depletion of V?2+ ?? T cells in live (in vivo) mice, allowing researchers to study the roles of these cells in immune responses, infections, tumors, and autoimmune processes.
• Mechanisms of action: Cell depletion is achieved via activation of innate immune effectors (such as phagocytes or cytotoxic cells) triggered by the antibody binding to the V?2 TCR on the target cells.

Researchers commonly use this antibody for:

• Cell depletion experiments: Directly eliminating a precise ?? T cell subset to determine its biological relevance.
• Flow cytometry: Identification and quantification of V?2+ ?? T cells in tissues.

Researchers are advised to consult specific protocols and dosing references on the supplier's product page or relevant literature to ensure optimal and reproducible results for their specific experimental context.

In the literature, the UC3-10A6 antibody, which targets mouse V?2 TCR, is often used alongside other antibodies and proteins for various studies, particularly in flow cytometry and immune cell analysis. Some commonly used antibodies include:

• Anti-CD3? (e.g., 145-2C11): This antibody is used to identify T cells broadly, including both ?? and ?? T cells.
• Anti-TCR? (e.g., GL3): Specifically identifies ? chain of the TCR, thus targeting ?? T cells.
• Anti-MHC class II (e.g., M5/114.15.2): Useful for identifying antigen-presenting cells like dendritic cells and macrophages.
• Anti-CD45.2 (e.g., 104) and Anti-CD45.1 (e.g., A20): These are used to distinguish between different mouse strains based on their CD45 allelic markers.
• Anti-IL-17A (e.g., ebio17B7): Important for studying cytokine production in immune responses.

These antibodies help in comprehensive analysis of immune cell populations and their functions, especially when studying ?? T cells and their roles in immunity.

Clone UC3-10A6 is a monoclonal antibody that recognizes the mouse T cell receptor (TCR) V?2 segment and has been extensively used in immunological research. The scientific literature reveals several key findings from studies utilizing this clone.

Malaria Infection Studies

Research on murine malaria infection has revealed significant insights about ?? T cell responses using UC3-10A6. During malaria infection, ?? T cells undergo substantial clonal expansion, with 37 to 48 expanded clones identified among sequenced cells in infected animals, compared to only one or two expanded clones in uninfected controls. Remarkably, approximately 75% of ?? T cells with identified TCR chains belonged to expanded clones in infected mice, versus only 2% in uninfected animals.

The studies identified a specialized ?? T cell subset that produces macrophage colony-stimulating factor (M-CSF), which appears to fulfill a protective role during the later stages of malaria infection when conventional ?? T cells are involved. This finding suggests an important regulatory function for these cells in the immune response to parasitic infections.

TCR Repertoire and Antigen Recognition

Single-cell TCR sequencing studies have revealed that during malaria infection, ?? T cells predominantly utilize the TRAV15N-1 (V?6.3) gene segment, with an average of 74% of ?? T cell clones from infected animals expressing this segment compared to only 15% in uninfected controls. This dramatic skewing indicates antigen-driven expansion and suggests these cells have narrow antigen specificity.

The ?-CDR3 sequences of expanded clones showed convergence toward specific amino acid motifs, including enrichment for clones containing the IGGI motif and hydrophobic amino acids in particular positions. This convergence further supports the concept that the expansion is driven by specific antigen recognition rather than random proliferation.

Autoimmune Disease Research

Studies on autoimmune arthritis have demonstrated the pathogenic role of V?4+ (equivalent to V?2 in Garman nomenclature) ?? T cells. Mice depleted of V?4+ cells using UC3-10A6 showed significant reductions in total IgG and IgG2a anti-collagen antibodies, as well as decreased disease severity and incidence of arthritis. These findings indicate that certain ?? T cell subsets can contribute to autoimmune pathology through antibody production and inflammatory responses.

Functional Characteristics

The UC3-10A6 antibody has proven effective for both analytical and functional studies. It successfully depletes ?? T cells when administered in vivo, making it a valuable tool for studying the role of these cells in various disease models. The antibody recognizes an epitope on the delta chain of the mouse V?2 TCR, and V?2-expressing T lymphocytes constitute a significant proportion of ?? T cells in multiple tissues including thymus, peripheral lymphoid organs, lung, intestinal epithelium, and epidermis.

These findings collectively demonstrate that UC3-10A6 has been instrumental in revealing the diverse roles of ?? T cells in infection, autoimmunity, and tissue homeostasis, while highlighting their capacity for antigen-specific responses and functional specialization in different disease contexts.

The specific dosing regimens of clone UC3-10A6 for depleting V?2 TCR-expressing ?? T cells in mouse models are not standardized and can vary depending on experimental design, target tissue, and desired duration or depth of depletion. However, available data provide some guidance:

• UC3-10A6 is an Armenian hamster IgG monoclonal antibody used primarily for in vivo ?? T cell depletion in mice.
• Typical research practice for depletion antibodies (based on similar clones' usage) is a dosing range from 100–250 ?g per mouse per dose via intraperitoneal injection, administered every 3–7 days.
• The Bio X Cell specification page confirms its use for in vivo depletion but does not prescribe a universal dose, as regimens should be adapted to individual study needs, mouse strain, age, and target tissue.

Variability Across Mouse Models:

• Immunodeficient or immunocompromised mice: May require lower or less frequent dosing due to slower cell repopulation and increased sensitivity.
• Tissue-specific targeting (e.g., spleen vs. epithelium): Higher or repeated dosing may be required to achieve efficient depletion in tissues with dense ?? T cell populations (such as mucosa or skin).
• Acute vs. chronic experiments: For acute depletion, a single dose or two doses over the course of a week are sometimes sufficient. For chronic studies, ongoing doses (e.g., every 3–7 days) are used to maintain depletion.

Additional Considerations:

• Dosing may be titrated based on pilot depletion efficacy (flow cytometry analysis of residual ?? T cells in blood/tissues post-treatment).
• There is no evidence of major differences solely due to mouse strain, but immune status/age and tissue microenvironment can affect antibody penetration and depletion rate.

Summary Table: Representative Regimens (inferred from similar depletion antibodies and general practice, as UC3-10A6–specific published data is limited)

Directly referencing UC3-10A6–specific regimens in published literature is challenging due to limited explicit published protocols; the above guidance is adapted from manufacturer information and dosing conventions used for in vivo depletion antibodies in mice. Adjustments should be confirmed by empirical depletion in pilot cohorts.